Kwangmeyung Kim

This inventor holds 11 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Korea Institute of Science and Technology, Korea University Research and Business Foundation. Active years: 2013-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kwangmeyung Kim. Retrieved from https://idiyas.com/inventor/kwangmeyung-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 5)

% Patents Active = 81.8

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 20(Granted Patents)

Company Filing History:

11 out of 2,248

Korea Institute of Science and Technology

patents

1 out of 1,274

Korea University Research and Business Foundation

patents

where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11833204 - Visible light-activatable nanoparticles for cancer immunotherapy and use thereof (2023-12-05),

2. 11498946 - Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients (2022-11-15),

3. 11246939 - Immunoregulatory protein-siRNA complex having anticancer activity (2022-02-15),

4. 11015197 - Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite (2021-05-25),

5. 10905774 - Nanocage and use thereof (2021-02-02),

6. 10610602 - Tumor cell-specific responsive self-assembling drug nanoconjugate (2020-04-07),

7. 10213515 - Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same (2019-02-26),

8. 10206987 - Protein nanoparticle linked with cancer specific epitope and composition for cancer immunotherapy comprising the same (2019-02-19),

9. 8530047 - Method for polymerizing a small oligonucleotide, and use of a high-molecular oligonucleotide prepared by the polymerization method (2013-09-10),

10. 8513402 - Human serum albumin-siRNA nano-sized carrier system (2013-08-20),

11. 8367042 - Nanoparticles of light emissive polymers and preparation method thereof (2013-02-05),

Title: Innovations of Kwangmeyung Kim in Cancer Therapy

Introduction

Kwangmeyung Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer therapy, holding a total of 11 patents. His work focuses on developing innovative solutions that enhance the efficacy of cancer treatments.

Latest Patents

Among his latest patents is the invention of visible light-activatable nanoparticles for cancer immunotherapy. These nanoparticles are designed to induce potent apoptosis in cancer cells while increasing their own anticancer immunogenicity. This innovation maximizes therapeutic efficacy against cancer. Another notable patent is a pharmaceutical composition for combination therapy aimed at preventing or treating cancer. This composition includes a tumor-specific drug conjugate and an anti-PD-L1 antibody as active ingredients. It has shown significant inhibition of cancer growth in in-vivo experiments and enhances the immunotherapeutic effect by activating immune cells in cancerous tissues. The composition demonstrates superior tumor accumulation efficiency and selectivity compared to existing anticancer agents, with minimal toxicity to normal tissues.

Career Highlights

Kwangmeyung Kim has worked with esteemed institutions such as the Korea Institute of Science and Technology and the Korea University Research and Business Foundation. His research and innovations have positioned him as a key figure in the development of advanced cancer therapies.

Collaborations

He has collaborated with notable colleagues, including Ick Chan Kwon and Ju Hee Ryu, contributing to the advancement of cancer treatment technologies.

Conclusion

Kwangmeyung Kim's innovative work in cancer therapy showcases his dedication to improving treatment outcomes for patients. His patents reflect a commitment to harnessing technology for better health solutions.

Profile summary based on public USPTO records.